Sipuleucel-T
- Generic Name
- Sipuleucel-T
- Brand Names
- Provenge
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 917381-47-6
- Unique Ingredient Identifier
- 8Q622VDR18
- Background
Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared specifically for each patient. In metastat...
- Indication
Sipuleucel-T is an autologous cellular immunotherapy indicated for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer.
- Associated Conditions
- Asymptomatic, metastatic hormone-refractory Prostate cancer, Minimally symptomatic, metastatic hormone-refractory Prostate cancer
- Associated Therapies
- -
Sipuleucel-T Combined with Bipolar Androgen Therapy in Men with MCRPC
- Conditions
- Interventions
- First Posted Date
- 2023-10-25
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Yale University
- Target Recruit Count
- 26
- Registration Number
- NCT06100705
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-03-02
- Last Posted Date
- 2024-11-14
- Target Recruit Count
- 26
- Registration Number
- NCT05751941
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer
- First Posted Date
- 2018-09-27
- Last Posted Date
- 2024-10-08
- Lead Sponsor
- Dendreon
- Target Recruit Count
- 532
- Registration Number
- NCT03686683
- Locations
- 🇺🇸
Johns Hopkins University School of Medicine, Baltimore, Maryland, United States
🇺🇸VA Greater Los Angeles Healthcare System, Los Angeles, California, United States
🇺🇸University of California Irvine, Orange, California, United States
Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-01-18
- Last Posted Date
- 2021-05-26
- Lead Sponsor
- University of Hawaii
- Target Recruit Count
- 37
- Registration Number
- NCT03024216
- Locations
- 🇺🇸
Prostate Oncology Specialists, Inc., Marina Del Rey, California, United States
🇺🇸City of Hope National Medical Center, Duarte, California, United States
🇺🇸University of Hawaii Cancer Center, Honolulu, Hawaii, United States
Men With Metastatic Castrate-Resistant Prostate Cancer Treated With Either Sipuleucel-T (Provenge®), Abiraterone Acetate (Zytiga®) or Enzalutamide (Xtandi®) Undergoing Cardiopulmonary EXercise Testing
- Conditions
- Interventions
- First Posted Date
- 2015-02-03
- Last Posted Date
- 2020-12-24
- Lead Sponsor
- Duke University
- Target Recruit Count
- 38
- Registration Number
- NCT02353715
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T
- Conditions
- First Posted Date
- 2014-09-05
- Last Posted Date
- 2019-01-09
- Lead Sponsor
- GenesisCare USA
- Target Recruit Count
- 20
- Registration Number
- NCT02232230
- Locations
- 🇺🇸
21st Century Oncology, Scottsdale, Arizona, United States
Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-01-15
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- Duke University
- Target Recruit Count
- 20
- Registration Number
- NCT02036918
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-04-16
- Last Posted Date
- 2017-08-24
- Lead Sponsor
- Prostate Oncology Specialists, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01832870
- Locations
- 🇺🇸
Prostate Oncology Specialists, Inc., Marina del Rey, California, United States
Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)
- Conditions
- Interventions
- First Posted Date
- 2013-03-27
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 20
- Registration Number
- NCT01818986
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.